O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2022 Sep 16

PMID 36110252

Authors

Lixia Zhou

Huiqin Wu

Xingli Bai

Shuyun Min

Jiawen Zhang

Cunli Li

Affiliations

Soon will be listed here.

Abstract

Identification of novel biomarkers is helpful for the diagnosis and treatment of cervical cancer. Mucin glycosylating enzyme GALNT2 modulates mucin O-glycosylation, and has been revealed as a regulator of tumorigenesis in various cancers. However, the expression pattern of GALNT2 in cervical cancer is still unclear. In this study, we demonstrated that the mRNA expression and protein level of GALNT2 were increased in cervical high-grade intraepithelial neoplasia and tumor tissues compared with normal cervix tissues. Kaplan-Meier plotter showed that overexpression of GALNT2 was associated with worse overall survival in TCGA cohort ( < 0.001, HR = 2.65, 95% CI = 1.62-4.34) and poor disease free survival in GSE44001 cohort ( = 0.0218, HR = 2.15, 95% CI = 1.14-4.06). In addition, GSEA analysis showed that various immune-related pathways were closely related to the expression of GALNT2 in cervical cancer. Moreover, co-expression of GALNT2 and IL1A, IL1B, IL11, CXCL1, CXCL2, CXCL5, CXCL6, CXCR1, or CCR3 predicted poor overall survival, and the expression of GALNT2 also affected the prognostic value of CD47, CD274, CD276, CSF1R, TNFSF9, and TNFSF11 in cervical cancer patients. These findings suggest that GALNT2 might be used as a prognostic biomarker in cervical cancer.

Citing Articles

The Value of CXCL1, CXCL2, CXCL3, and CXCL8 as Potential Prognosis Markers in Cervical Cancer: Evidence of E6/E7 from HPV16 and 18 in Chemokines Regulation.

Fernandez-Avila L, Castro-Amaya A, Molina-Pineda A, Hernandez-Gutierrez R, Jave-Suarez L, Aguilar-Lemarroy A Biomedicines. 2023; 11(10).

PMID: 37893029 PMC: 10604789. DOI: 10.3390/biomedicines11102655.

Exploration of glycosyltransferases mutation status in cervical cancer reveals PARP14 as a potential prognostic marker.

Wang H, Luo S, Wu X, Ruan Y, Qiu L, Feng H Glycoconj J. 2023; 40(5):513-522.

PMID: 37650946 PMC: 10638145. DOI: 10.1007/s10719-023-10134-7.

The sub-molecular characterization identification for cervical cancer.

Mo X, Wang N, He Z, Kang W, Wang L, Han X Heliyon. 2023; 9(6):e16873.

PMID: 37484385 PMC: 10360967. DOI: 10.1016/j.heliyon.2023.e16873.

References

Guo L, Hua K . Cervical Cancer: Emerging Immune Landscape and Treatment. Onco Targets Ther. 2020; 13:8037-8047. PMC: 7434518. DOI: 10.2147/OTT.S264312. View

Marucci A, di Mauro L, Menzaghi C, Prudente S, Mangiacotti D, Fini G . GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia. PLoS One. 2013; 8(7):e70159. PMC: 3718685. DOI: 10.1371/journal.pone.0070159. View

Sahasrabudhe N, van der Horst J, Spaans V, Kenter G, de Kroon C, Bosse T . MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. Front Oncol. 2019; 9:29. PMC: 6361794. DOI: 10.3389/fonc.2019.00029. View

Lairson L, Henrissat B, Davies G, Withers S . Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem. 2008; 77:521-55. DOI: 10.1146/annurev.biochem.76.061005.092322. View

Sun Z, Xue H, Wei Y, Wang C, Yu R, Wang C . Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis. Clin Sci (Lond). 2019; 133(10):1167-1184. DOI: 10.1042/CS20190145. View

Lin M, Huang M, Liu C, Yang T, Huang M . GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol. 2014; 50(5):478-84. DOI: 10.1016/j.oraloncology.2014.02.003. View

Kong W, Zhao G, Chen H, Wang W, Shang X, Sun Q . Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment. Cancer Cell Int. 2021; 21(1):399. PMC: 8317415. DOI: 10.1186/s12935-021-02101-9. View

Wang W, Sun R, Zeng L, Chen Y, Zhang N, Cao S . GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma. Life Sci. 2021; 276:119439. DOI: 10.1016/j.lfs.2021.119439. View

Khetarpal S, Schjoldager K, Christoffersen C, Raghavan A, Edmondson A, Reutter H . Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. Cell Metab. 2016; 24(2):234-45. PMC: 5663192. DOI: 10.1016/j.cmet.2016.07.012. View

10.

Nagy A, Munkacsy G, Gyorffy B . Pancancer survival analysis of cancer hallmark genes. Sci Rep. 2021; 11(1):6047. PMC: 7961001. DOI: 10.1038/s41598-021-84787-5. View

11.

Santaella-Verdejo A, Gallegos B, Perez-Campos E, Hernandez P, Zenteno E . Use of amaranthus leucocarpus lectin to differentiate cervical dysplasia (CIN). Prep Biochem Biotechnol. 2007; 37(3):219-28. DOI: 10.1080/10826060701386703. View

12.

Wu Y, Liu C, Hu R, Huang M, Lee J, Chen C . Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011; 71(23):7270-9. DOI: 10.1158/0008-5472.CAN-11-1161. View

13.

Thomas D, Rathinavel A, Radhakrishnan P . Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188464. PMC: 7855613. DOI: 10.1016/j.bbcan.2020.188464. View

14.

Alexander K, Serrano C, Chakraborty A, Nearing M, Council L, Riquelme A . Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover. J Biol Chem. 2020; 295(41):14153-14163. PMC: 7549044. DOI: 10.1074/jbc.RA120.014887. View

15.

Schjoldager K, Clausen H . Site-specific protein O-glycosylation modulates proprotein processing - deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim Biophys Acta. 2012; 1820(12):2079-94. DOI: 10.1016/j.bbagen.2012.09.014. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

18.

Marucci A, Cozzolino F, Dimatteo C, Monti M, Pucci P, Trischitta V . Role of GALNT2 in the modulation of ENPP1 expression, and insulin signaling and action: GALNT2: a novel modulator of insulin signaling. Biochim Biophys Acta. 2013; 1833(6):1388-95. DOI: 10.1016/j.bbamcr.2013.02.032. View

19.

Lin W, Yeh C . GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. Int J Mol Sci. 2020; 21(4). PMC: 7073045. DOI: 10.3390/ijms21041491. View

20.

Liu S, Shun C, Hung K, Juan H, Hsu C, Huang M . Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation. Oncotarget. 2016; 7(10):11251-62. PMC: 4905470. DOI: 10.18632/oncotarget.7081. View